Osiris Therapeutics (NASDAQ: OSIR) and Soligenix (OTC:SNGX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings and analyst recommendations.

Valuation & Earnings

This table compares Osiris Therapeutics and Soligenix’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Osiris Therapeutics $86.60 million 2.31 $4.41 million N/A N/A
Soligenix $9.15 million N/A -$5.45 million N/A N/A

Osiris Therapeutics has higher revenue and earnings than Soligenix.

Institutional and Insider Ownership

19.9% of Osiris Therapeutics shares are held by institutional investors. 44.6% of Osiris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Osiris Therapeutics and Soligenix, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Osiris Therapeutics 0 0 0 0 N/A
Soligenix 0 0 2 0 3.00

Soligenix has a consensus target price of $8.00, indicating a potential upside of 250.88%. Given Soligenix’s higher possible upside, analysts plainly believe Soligenix is more favorable than Osiris Therapeutics.

Profitability

This table compares Osiris Therapeutics and Soligenix’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Osiris Therapeutics -2.60% -3.13% -2.59%
Soligenix -233.27% -196.47% -122.14%

Summary

Osiris Therapeutics beats Soligenix on 7 of the 9 factors compared between the two stocks.

Osiris Therapeutics Company Profile

Osiris Therapeutics, Inc. is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body’s natural healing. The Company’s products include Grafix, Stravix, TruSkin, Cartiform and BIO4. The Company produces and distributes Grafix for acute and chronic wounds; Stravix for tendon repair; TruSkin for wound closure; Cartiform, a viable cartilage mesh for cartilage repair, and BIO4 for bone growth. The Company’s BioSmart cryopreservation process retains the native characteristics and inherent functionality of tissue. Its BioSmart process includes preservation of the three dimensional (3D) matrix, endogenous growth factors, and tissue-resident cells.

Soligenix Company Profile

Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate.

Receive News & Ratings for Osiris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osiris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.